儿童和青少年颅咽管瘤术后内分泌管理专家共识

doi:10.16352/j.issn.1001-6325.2024.05.0585

摘要/Abstract

摘要： 颅咽管瘤是发生于儿童鞍区的少见良性肿瘤,术后患者可长期存活。因肿瘤及手术常损害下丘脑和垂体功能,导致下丘脑综合征、垂体前叶功能减退症、肥胖、电解质紊乱等一系列功能异常,需内分泌科为主的多学科团队进行长期的精细的激素治疗和随访管理。本共识针对此类人群,围绕围手术期管理、肥胖管理、激素替代、身高增长和青春发育等主题,制定规范化的长期随访管理建议,以提高临床医生的应对水平和患者的健康状态。

关键词: 儿童和青少年, 颅咽管瘤, 下丘脑综合征, 激素替代治疗, 身高, 青春发育

Abstract: Craniopharyngioma is a rare benign tumor mainly occurs in the hypothalamus region of children. Patients may have a long survival after surgery. Tumors or operations may lead to hypothalamic syndrome, hypopituitarism, obesity, and a disturbed electrolytes metabolism. Multidisciplinary medical teams are required to conduct a long-term hormonal therapy and follow-up management. This consensus is aiming for providinge recommendations for perioperative management, obesity, hormonal replacement therapy, linear growth promotion and pubertal development for pediatric patients.

Key words: children and adolescents, craniopharyngioma, hypothalamic syndrome, hormonal replacement therapy, height promotion, pubertal development

中图分类号:

R584.2

中国老年保健协会生长发育和性腺疾病分会. 儿童和青少年颅咽管瘤术后内分泌管理专家共识[J]. 基础医学与临床, 2024, 44(5): 585-598.

Growth and Development and Gonadal Diseases Committee of Chinese Aging Well Association. Consensus on endocrine management for children and adolescents with craniopharyngioma surgeries[J]. Basic & Clinical Medicine, 2024, 44(5): 585-598.

参考文献

[1] Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group[J]. Lancet, 2001, 357(9254): 425-431.
[2] Grimberg A, Divall SA, Polychronakos C, et al. Guide-lines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency[J]. Horm Res Paediatr, 2017, 86(6): 361-397.
[3] 中华医学会内分泌学分会肥胖学组. 肾上腺皮质功能减退症患者围手术期糖皮质激素管理专家共识[J]. 中华内分泌代谢杂志, 2022, 38(1): 1-6.
[4] Edate S, Albanese A. Management of electrolyte and fluid disorders after brain surgery for pituitary/suprasellar tumours[J]. Horm Res Paediatr, 2015, 83(5): 293-301.
[5] Patti G, Ibba A, Morana G, et al. Central diabetes insipidus in children: diagnosis and management[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(5): 101440.
[6] Atila C, Loughrey PB, Garrahy A, et al. Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey[J]. Lancet Diabetes Endocrinol, 2022, 10(10): 700-709.
[7] 姜兰叶, 徐剑, 钟历勇. 颅咽管瘤183例临床分析[J].中国医师进修杂志, 2008, 31(9): 18-21.
[8] Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab,2016, 101(11): 3888-3921.
[9] Mongioi LM, Condorelli RA, Barbagallo F, et al. Dual-release hydrocortisone for treatment of adrenal insuffici-ency: a systematic review[J]. Endocrine, 2020, 67(3): 507-515.
[10] Rushworth RL, Torpy DJ, Falhammar H. Adrenal crisis[J]. N Engl J Med, 2019, 381(9): 852-861.
[11] 苗玉麒, 吴迪. 儿童颅咽管瘤术后内分泌评估及激素替代治疗[J]. 中国实用儿科杂志, 2020, 35(6): 446-450.
[12] Benvenga S. L-T4 Therapy in the Presence of Pharmacological Interferents[J]. Front Endocrinol (Lausanne),2020, 11: 607446.
[13] 王慕逖. 中枢性甲状腺功能减退症[J]. 临床儿科杂志, 1993, 11(5): 2-4.
[14] Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism. prepared by the american thyroid association task force on thyroid hormone replacement[J]. Thyroid, 2014, 24(12): 1670-1751.
[15] Miguel GA, Plá AS, Muñoz MLP, et al. Seven years of follow-up of trabecular bone score, bone mineral density, body composition and quality of life in adults with growth hormone deficiency treated with rhGH replacement in a single center[J]. Ther Adv Endocrinol Metab,2016, 7(3): 93-100.
[16] Boguszewski MCS, Boguszewski CL, Chemaitilly W, et al. Safety of growth hormone replacement in survivors of cancer and Intracranial and pituitary tumours: a consensus statement[J]. Eur J Endocrinol, 2022, 186(6): 35-52.
[17] Nguyen Quoc A, Beccaria K, Briceño LG, et al. GH and childhood-onset craniopharyngioma: when to initiate growth hormone replacement therapy?[J]. J Clin Endocrinol Metab, 2023, 108(8): 1929-1936.
[18] 颅咽管瘤治疗专家共识编写委员会, 中华医学会神经外科学分会小儿神经外科学组. 颅咽管瘤患者长期内分泌治疗专家共识(2017)[J]. 中华医学杂志, 2018, 98(1): 11-18.
[19] Smith TR, Cote DJ, Jane JA, et al. Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the genentech national cooperative growth study[J]. J Neurosurg Pediatr, 2016, 18(4): 408-412.
[20] Alotaibi NM, Noormohamed N, Cote DJ, et al. Physio-logic growth hormone-replacement therapy and craniopharyngioma recurrence in pediatric patients: a meta-analysis[J]. World Neurosurg, 2018, 109: 487-496.e1.
[21] Tamhane S, Sfeir JG, Kittah NEN, et al. GH therapy in childhood cancer survivors: a systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2018, 103(8): 2794-2801.
[22] Olsson DS, Buchfelder M, Wiendieck K, et al. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up[J]. Eur J Endocrinol, 2012, 166(6): 1061-1068.
[23] 中华医学会儿科学分会内分泌遗传代谢学组,中华儿科杂志编辑委员会. 过渡期生长激素缺乏症诊断及治疗专家共识[J]. 中华儿科杂志, 2020, 58 (6): 455-460.
[24] Richmond E, Rogol AD. Treatment of growth hormone deficiency in children, adolescents and at the transitional age[J]. Best Pract Res Clin Endocrinol Metab, 2016, 30(6): 749-755.
[25] 中华医学会内分泌学分会. 成人生长激素缺乏症诊治专家共识 (2020版)[J]. 中华内分泌代谢杂志, 2020, 36(12): 995-1002.
[26] 茅江峰, 王曦, 熊舒煜, 等. 重组人生长激素替代治疗对颅咽管瘤术后成人患者代谢指标的影响[J]. 中华医学杂志, 2017, 97(42): 3286-3290.
[27] Zhang XY, Yuan K, Fang YL, et al. Growth hormone ameliorates hepatopulmonary syndrome and nonalcoholic steatohepatitis secondary to hypopituitarism in a child: A case report[J]. World J Clin Cases, 2022, 10(18): 6211-6217.
[28] Amayiri N, Spitaels A, Zaghloul M, et al. SIOP PODC-adapted treatment guidelines for craniopharyngioma in low- and middle-income settings[J]. Pediatr Blood Cancer, 2023, 70(11): e28493.
[29] Mao JF, Xu HL, Wang X, et al. Congenital combined pituitary hormone deficiency patients have better responses to gonadotrophin-induced spermatogenesis than idiopathic hypogonadotropic hypogonadism patients[J]. Hum Reprod, 2015, 30(9): 2031-2037.
[30] 孙首悦,王卫庆,蒋怡然, 等. 微量泵脉冲输注戈那瑞林治疗特发性低促性腺激素性性腺功能减退症[J]. 中华内分泌代谢杂志, 2011, 27(8): 654-658.
[31] Ma W, Mao J, Nie M, et al. Gonadotropin therapy once a week for spermatogenesis in hypogonadotropic hypogonadism[J]. Endocr Pract, 2021, 27(11): 1119-1127.
[32] Otte A, Müller HL. Childhood-onset Craniopharyngioma[J]. J Clin Endocrinol Metab, 2021,106(10):e3820-e3836.
[33] Du C, Leng YS, Zhou QW, et al. Relationship between postoperative hypothalamic injury and water and sodium disturbance in patients with craniopharyngioma: a retrospective study of 178 cases[J]. Front Endocrinol (Lausanne), 2022, 13: 958295.
[34] Thompson CJ, Costello RW, Crowley RK. Management of hypothalamic disease in patients with craniopharyn-gioma[J]. Clin Endocrinol(Oxf), 2019, 90(4): 506-516.
[35] Crowley RK, Woods C, Fleming M, et al. Somnolence in adult craniopharyngioma patients is a common, heterogeneous condition that is potentially treatable[J]. Clin Endocrinol (Oxf),2011, 74(6): 750-755.
[36] Cajochen C, Kräuchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep[J]. J Neuroendocrinol, 2003, 15(4): 432-437.
[37] Müller HL,Gebhardt U, Teske C, et al. Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up[J]. Eur J Endocrinol, 2011, 165(1): 17-24.
[38] Müller HL, Emser A, Faldum A, et al. Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma[J]. J Clin Endocrinol Metab, 2004, 89(7): 3298-305.
[39] Laura VL, Brokke KE, Adan RAH, et al. Pathophysio-logy and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review[J]. Endocr Rev, 2019, 40(1): 193-235.
[40] Müller HL, Bueb K, Bartels U, et al. Obesity after childhood craniopharyngioma--German multicenter study on pre-operative risk factors and quality of life[J]. Klin Padiatr, 2001, 213(4): 244-249.
[41] Wu W, Sun QY, Zhu XM, et al. Risk factors for hypothalamic obesity in patients with adult-onset craniopharyngioma: a consecutive series of 120 cases[J]. Front Endocrinol (Lausanne), 2021, 12: 694213.
[42] Van Iersel L, Meijneke RWH, Meeteren AYNS,et al. The development of hypothalamic obesity in craniopharyngioma patients: a risk factor analysis in a well-defined cohort[J]. Pediatr Blood Cancer, 2018, 65(5): e26911.
[43] Holmer H, Ekman B, Björk J, et al. Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy[J]. Eur J Endocrinol, 2009, 161(5): 671-679.
[44] Mong S, Pomeroy SL, Cecchin F, et al. Cardiac risk after craniopharyngioma therapy[J]. Pediatr Neurol, 2008, 38(4):256-260.
[45] Page-Wilson G, Wardlaw SL, Khandji AG, et al. Hypothalamic obesity in patients with craniopharyngioma: treatment approaches and the emerging role of gastric bypass surgery[J]. Pituitary, 2012, 15(1): 84-92.
[46] Elowe-Gruau E, Beltrand J, Brauner R, et al. Childhood craniopharyngioma: hypothalamus-sparing surgery decreases the risk of obesity[J]. J Clin Endocrinol Metab, 2013, 98(6): 2376–2382.
[47] Rakhshani N, Jeffery AS, Schulte F, et al. Evaluation of a comprehensive care clinic model for children with brain tumor and risk for hypothalamic obesity[J]. Obesity (Silver Spring) 2010, 18(9): 1768–1774.
[48] Sterkenburg AS, Hoffmann A, Gebhardt U, et al. Childhood craniopharyngioma with hypothalamic obesity-no long-term weight reduction due to rehabilitation programs[J]. Klin Padiatr, 2014, 226(6-7): 344-350.
[49] Meijneke RWH, Schouten-van Meeteren AYN, de Boer NY, et al. Hypothalamic obesity after treatment for craniopharyngioma: the importance of the home environment[J]. J Pediatr Endocrinol Metab, 2015, 28(1-2): 59-63.
[50] Skorzewska A, Lal S, Waserman J, et al. Abnormal food-seeking behavior after surgery for craniopharyngioma[J]. Neuropsychobiology, 1989, 21(1): 17-20.
[51] Steele CA, Cuthbertson DJ, MacFarlane IA, et al. Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendo-crine clinic[J]. Eur J Endocrinol, 2013, 168(4): 501-507.
[52] Ismail D, O′Connell MA, Zacharin MR. Dexampheta-mine use for management of obesity and hypersomnol-ence following hypothalamic injury[J]. J Pediatr Endocrinol Metab, 2006, 19(2): 129-134.
[53] Mason PW, Krawiecki N, Meacham LR. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma[J]. Arch Pediatr Adolesc Med, 2002, 156(9): 887-892.
[54] Horne VE, Bielamowicz K, Nguyen J, et al. Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity[J]. Pediatr Blood Cancer, 2020, 67(7): e28379.
[55] Kelly AS, Bensignor MO, Hsia DS, et al. Phentermine/topiramate for the treatment of adolescent obesity[J]. NEJM Evid, 2022, 1(6): 10.1056/evidoa2200014.
[56] Greenway FL, Bray GA. Treatment of hypothalamic obesity with caffeine and ephedrine[J]. Endocr Pract, 2008, 14(6): 697-703.
[57] Roth CL, Perez FA, Whitlock KB, et al. A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity[J]. Diabetes Obes Metab, 2021, 23(2): 363-373.
[58] Zoicas F, Droste M, Mayr B, et al. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases[J]. Eur J Endocrinol, 2013, 168(5): 699-706.
[59] Courcoulas AP, Belle SH, Neiberg RH, et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial[J]. JAMA Surg, 2015, 150(10): 931-940.
[60] van Iersel L, Brokke KE, Adan RAH, et al. Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review[J]. Endocr Rev,2019,40(1):193-235.
[61] Wijnen M, Olsson DS, van den Heuvel-Eibrink MM, et al. Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched case-control study with 2 years of follow-up[J]. Int J Obes (Lond), 2017, 41(2): 210-216.
[62] Weismann D, Pelka T, Bender G, et al. Bariatric surgery for morbid obesity in craniopharyngioma[J]. Clin Endocrinol (Oxf), 2013, 78(3): 385-390.
[63] Muller HL, Gebhardt U, Maroske J, et al. Long-term follow up of morbidly obese patients with childhood craniopharyngioma after laparoscopic adjustable gastric banding (LAGB)[J]. Klin Padiatr, 2011, 223(6): 372-373.
[64] van Santen SS, Olsson DS, van den Heuvel-Eibrink MM, et al. Fractures, bone mineral density, and final height in craniopharyngioma patients with a follow-up of 16 years[J]. J Clin Endocrinol Metab, 2020, 105(4): e1397-e1407..
[65] Koppel BS, Harden CL, Nikolov BG, et al. An analysis of lifetime fractures in women with epilepsy[J]. Acta Neurol Scand, 2005, 111(4): 225-228.
[66] Holmer H, Popovic V, Ekman B, et al. Hypothalamic involvement and insufficient sex steroid supplementation are associated with low bone mineral density in women with childhood onset craniopharyngioma[J]. Eur J Endocrinol, 2011, 165(1): 25-31.
[67] Mazziotti G, Frara S, Giustina A. Pituitary diseases and bone[J]. Endocrine Rev, 2018, 39(4): 440-488.
[68] Van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses[J]. Rheumatology (Oxford), 2000, 39(12): 1383-1389.
[69] Van Santen SS, Olsson DS, Hammarstrand C, et al. Body composition and bone mineral density in craniopharyngi-oma patients: a longitudinal study over 10 years[J]. J Clin Endocrinol Metab, 2020, 105(12): dgaa607.
[70] Muller HL. Childhood craniopharyngioma[J]. Pituitary, 2013, 16(1): 56-67.
[71] Caldarelli M, Massimi L, Tamburrini G, et al. Long-term results of the surgical treatment of craniopharyngioma: the experience at the Policlinico Gemelli, Catholic University, Rome[J]. Childs Nerv Syst, 2005, 21(8-9): 747-757.
[72] Elliott RE, Wisoff JH. Surgical management of giant pediatric craniopharyngiomas[J]. Neuro-surg Pediatr, 2010,6(5): 403-416.
[73] Michal C, Sharon G, Jill H. Long term sequelae of pediatric craniopharyngioma-literature review and 20 years of experience[J]. Front Endocrinol(Lausanne), 2011, 2: 81.
[74] Cossu G, Jouanneau E, Cavallo LM, et al. Surgical management of craniopharyngiomas in adult patients: a systematic review and consensus statement on behalf of the EANS skull base section[J]. Acta Neurochir (Wien), 2020, 162(5): 1159-1177.
[75] Toaz E, Benzon H. Perioperative management of the pediatric patient with craniopharyngioma[C].https://snacc.org/wp-content/uploads/2022/06/Perioperative-Management-of-the-Pediatric-Patient-with-Craniopharyngioma.pdf.
[76] Frič R, König M, Due-Tønnessen BJ, et al. Long-term outcome of patients treated for craniopharyngioma: a single center experience[J]. Br J Neurosurg, 2023, 17: 1-9.
[77] Komotar RJ, Robert MS, Raper DMS, et al. Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of craniopharyngiomas[J]. World Neurosurg, 2012, 77(2): 329-341.
[78] Sandvik U, Ohlsson M, Edström E. Vascular complica-tions in pediatric craniopharyngioma patients: a case-based update[J]. Child's Nerv Syst, 2019, 35(12): 2273-2278.
[79] Yano S, Kudo M, Hide T, et al. Quality of life and clinical features of long-term survivors surgically treated for pediatric craniopharyngioma[J]. World Neurosurg, 2016, 85: 153-162.
[80] Li SY, Wang X, Zhao YL, et al. Metabolic effects of recombinant human growth hormone replacement therapy on juvenile patients after craniopharyngioma resection[J]. Int J Endocrinol, 2022, 2022: 7154907.
[81] Reyes M, Taghvaei M, Yu S, et al. Targeted therapy in the management of modern craniopharyngiomas[J]. Front Biosci (Landmark Ed), 2022, 27(4): 136-150.
[82] Lara-velazquez M, Mehkri Y, Panther E, et al. Current advances in the management of adult craniopharyngiomas[J]. Curr Oncol, 2022, 29(3): 1645-1671.
[83] Iglesias P. Targeted therapies in the medical management of craniopharyngioma[J]. Pituitary, 2022, 25(3): 383-392.
[84] 罗杰, 姚辉. 颅咽管瘤患儿远期生存质量影响因素研究进展[J]. 国际儿科学杂志, 2021, 48(11): 753-756.
[85] Conklin HM, Ness KK, Ashford JM, et al. Cognitive performance, aerobic fitness, motor proficiency, and brain function among children newly diagnosed with craniopharyngioma[J]. J Int Neuropsychol Soc, 2019, 25(4): 413-425.
[86] Shoemaker AH, Tamaroff J. Approach to the patient with hypothalamic obesity[J]. J Clin Endocrinol Metab, 2023, 108(5): 1236-1242.
[87] 李丽嫱, 桂松柏, 宫健, 等. 儿童颅咽管瘤全切术后并发症的分析[J].解放军预防医学杂志, 2019, 37(6): 134-135.